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Objective: Recent hypertension guidelines recommend initiation of treatment with a fixed
dose combination of two drugs for more effective and quicker blood pressure control. Few
of these have been assessed for efficacy and acceptability. This study examines the short
term blood pressure control and acceptability of perindopril, with or without its fixed dose
combinations (FDC) with amlodipine and Indapamide in younger patients.
Methods: In a multicentre prospective observational study, patients with stage 1 hyper-
tension were prescribed perindopril 4 mg per day. Those with stage 2 or 3 hypertension
were prescribed a single tablet per day of 4 mg perindopril and 5 mg amlodipine (COVERSYL
AM), or 4 mg perindopril and 1.25 mg indapamide (COVERSYL PLUS)for 45 days. The pri-
mary outcomes were the frequency of patients achieving blood pressure control and the
adverse effect of pedal edema.
Results: Of 426 patients, with a mean age of 45 years, distributed throughout India, and an
average (SD) baseline systolic/diastolic blood pressure of 157.2 (13.5)/98.6 (7.4), 303 (71.1%)
achieved blood pressure control. Mean (SD) SBP/DBP decreased from baseline by 26.9 (12.6),
and DBP by 15.4 (7.2) mm Hg. Few patients discontinued treatment, and the frequency of
cough that interfered with sleep and ankle edema was low.
Conclusion: In patients requiring combination antihypertensive treatment, the regimen of
perindopril alone or its FDC with Indapamide or amlodipine reduces blood pressure
effectively, resulting in high rates of blood pressure control over the short term, with a low
frequency of side effects including cough and pedal edema.
Copyright © 2014, Cardiological Society of India. All rights reserved.m (S. Bansal).
ociety of India. All rights reserved.
Table 1 e Baseline characteristics of treatment naı¨ve
patients with hypertension.
n ¼ 426
Age, years 45.2 ± 6.5
Male sex 289 (67.8)
Cardiovascular risk
Current smoker 90 (21.3)
Weight, kg 70.3 ± 10.2
Left ventricular hypertrophy 12 (2.8)
Diabetes 60 (14.1)
History of myocardial infarction 4 (1.0)
History of stroke 4 (1.0)
Family history of hypertension 80 (18.8)
Systolic blood pressure mmHg 157.2 ± 13.5
Diastolic blood pressure mmHg 98.6 ± 7.4
Stage 1 hypertension 280 (65.7)
Stage 2 hypertension 116 (27.2)
Stage 3 hypertension 30 (7.0)
Fasting plasma glucose mg/dl 109.8 ± 60.4
Total cholesterol mg/dl 205.3 ± 118.1
LDL cholesterol mg/dl Not assessed
HDL cholesterol mg/dl 47.5 ± 24.7
Serum creatinine mg/dl Not assessed
Plus minus values are means ± standard deviation. All other values
are numbers of patients followed by percentages of the group in
parenthesis.
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The presence of hypertension increases the risk of cardio-
vascular mortality,1 and its treatment reduces this risk.2 The
evidence, however, limited to older patients, and the benefit to
those who are younger is not clearly established.3
The importance of younger patients with hypertension in
countries such as India, is emphasized by cross-sectional
survey data, which showed that the average age of patients
with stage 1 and 2 was about 49 years.4 Hence, there is a need
to assess blood pressure lowering efficacy, acceptability, and
cardiovascular risk reduction with drug treatment regimens
in younger patients with hypertension. Recent guidelines
recommend initiating treatment with long acting once daily
formulations of an angiotensin converting enzyme inhibitor
(ACEI) in patients below 55 years, with the addition, if
required, of a calcium channel blocker (CCB), or thiazide like
diuretic such as Indapamide.3 In this respect, The ACEI peri-
ndopril has been shown to reduce the risk of cardiovascular
outcomes in combination with both amlodipine5 and inda-
pamide6 in hypertensive patients.
The objective of this multicenter, prospective, observa-
tional study was to assess short term blood pressure control
and acceptability of perindopril, with or without its fixed dose
combinations (FDC) with amlodipine and Indapamide in
younger patients.2. Patients and methods
2.1. Selection of study investigators
Of 468 Indian cities with a population of over 1 million in 2007,
40 were randomly selected. Primary care physicians in these
cities, and the metropolitan cities of Bombay, Calcutta, Delhi,Fig. 1 e Study flow chart.and Chennai were identified by their membership of the As-
sociation of Physicians of India, and invited to participate in
the study.2.2. Selection of patients
Each investigator selected consecutive outpatients between
40 and 56 years of either sex, with untreated essential hy-
pertension as suggested by European guidelines6 [Stage 1 hy-
pertension was a systolic blood pressure (SBP)/diastolic blood
pressure (DBP) equal to or greater than 140/90, but less than
160/100 mmHg; stage 2, equal to or greater than 160/100, but
less than 180/110 mmHg; and stage 3, equal to or greater than
180/110, mmHg]. Patients with secondary hypertension, any
chronic disease other than diabetes, a contraindication to the
use of perindopril, amlodipine or indapamide SR (Natrilix SR)
and who were pregnant or lactating were excluded.2.3. Study design, assessments, and follow up (Fig. 1)
After giving their written informed consent, patients were
assessed at baseline (Table 1) for demographic, clinical, prior
treatment, and biochemical characteristics. Patients with
stage 1 hypertension were prescribed perindopril 4 mg per
day. Those with stage 2 or 3 hypertension were prescribed an
FDC of 4mg perindopril and 5mg amlodipine (COVERSYL AM),
or 4 mg perindopril and 1.25 mg indapamide (COVERSYL
PLUS), to be taken with breakfast for 30 days. Treatment of
associated disease was allowed at the discretion of the local
physician. Patients were followed up and reassessed on the
30th, 60th and 90th day of the study. At each follow up visit,
blood pressure was measured, and patients were asked open
ended questions about side effects since the previous visit. All
Fig. 2 e Blood pressure response to treatment with perindopril its fixed dose combinationwith amlodipine or indapamide in
untreated hypertension.
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recommended conditions.3 Patients with BP under control
(systolic BP < 140, and diastolic BP < 90 mmHg) continued the
same treatment prescribed at baseline. Among patients not
achieving BP control on the 30th day of treatment, for those
with stage 1 hypertension, perindopril 4 mg was withdrawn
and replaced with 1 FDC tablet of COVERSYL AM or COVERSY
PLUS per day at breakfast for the next 30 days. Patients un-
controlled on COVERSYL PLUS or COVERSYL AM were with-
drawn from the study. All medications were required to be
purchased by patients from the market, as they could not be
provided within the resources of study.
2.4. Statistical analysis
The primary outcomes were the mean changes in blood
pressure from baseline after receiving the study treatment,
and the number of patients achieving blood pressure control
(SBP less than 140 and DBP less than 90 mmHg, including
those with diabetes) on an intention to treat basis. Other
outcomes were frequency of side effects reported by the pa-
tient and adherence with the study treatment. Significance
was defined as a p value of less than 0.05.3. Results
Primary care physicians (233), distributed throughout India
(from 40 cities), recruited 426 patients with untreated essen-
tial hypertension. Baseline characteristics are given in Table 1.
The average age of patients was 45.2 ± 6.5, median age 46.0,
and 75th percentile, 50 years; 67.8% were men; stage 1 hy-
pertension was present in 65.7%; stage 2 in 27.2%, and stage 3
in 7%. Diabetes was present in 14.1%, and 1% gave a history of
myocardial infarction or stroke.
3.1. Blood pressure response to treatment
For all patients taken together, mean (SD) SBP decreased by
26.9 (12.6), and DBP by 15.4 (7.2) mm Hg. As shown in Fig. 2, Inpatients with stage 1 hypertension who received initial mon-
otherapy with perindopril, followed, if required to achieve
blood pressure control, with its FDC with amlodipine or
indapamide, mean (95% Confidence interval, CI) baseline SBP
decreased by 21.4 (20.4e22.3), and baseline DBP by 12.4
(11.7e13.0) mmHg after 90 days of treatment.
Among patients with stage 2 hypertension, initiation of
treatment with the FDC of perindopril and amlodipine (in 73
patients) decreased baseline SBP by 35.2 (31.7e38.7) and DBP
by 20.6 (19.2e22.1) mmHg, while initial treatment with the
FDC of perindopril and indapamide (in 40 patients) decreased
baseline SBP by 35.7 (32.8e38.7) and DBP by 19.9
(17.6e22.1) mmHg.
In stage 3 hypertension, initiation of treatment with the
FDC of perindopril and amlodipine (in 17 patients) decreased
baseline SBP by 46.1 (40.1e52.3) and DBP by 23.8
(19.9e27.7) mmHg, while initial treatment with the FDC of
perindopril and indapamide (in 12 patients) decreased base-
line SBP by 41.8 (32.6e50.9) and DBP by 26.1 (21.4e30.7) mmHg.
3.1.1. Blood pressure control
Blood pressure control was achieved, on an intention-to-treat
basis, among 280 patients with stage 1 hypertension, in 185
(66.1%) with perindopril monotherapy; in an additional 18
(6.4%) with its indapamide FDC; and in an additional 12 (4.3%)
with its amlodipine FCD. Among 116 patients with stage 2
hypertension, control was attained in 25 out of 41 (55.6%) with
the FDC of perindopril and indapamide, and in 43 out of 75
(57.3%) with the FDC of perindopril and amlodipine. Of the 30
patients with stage 3 hypertension, control was reached in 3
out of 12 (25.0%) with the FDC of perindopril and indapamide,
and in 5 out of 18 (27.8%) with the FDC of perindopril and
amlodipine. Overall, 303 (71.1%) patients achieved blood
pressure control.
3.2. Withdrawals cough and other adverse effects
Seven patients (1.6%) discontinued treatment. These were,
among patients who received initial perindopril mono-
therapy, 4 (all lost to follow up); of those who received the FDC
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those who received the FDC of perindopril and indapamide, 2
lost to follow up.
Dry cough that interfered with sleep of patients was re-
ported, among those who received perindopril monotherapy,
in 10/280 (3.6%); of those taking the FDC of perindopril and
indapamide, in 1/140 (1.8%); and among those who received
the FDC of perindopril and amlodipine, in 4/93 (4.3%). Cough
led to discontinuation of treatment in 1/10 (0.1%). Of the other
adverse effects occurring at a frequency of more than 1, ankle
edema developed in 3/94 (3.2%) patients treated with the FDC
of perindopril and amlodipine.4. Discussion
This was a study on untreated, relatively young hypertensive
patients (75% were below the age of 50 years). The frequency
of diabetes, and cardiovascular risk factors was low, andmore
than two thirds presented with early hypertension. On an
intention to treat basis, over a 3 month period, treatment of
grade 1 hypertension with perindopril monotherapy,
decreased blood pressure sufficiently to control 66% of pa-
tients. A further 10% could be controlled by the FDC of peri-
ndopril with indapamide or amlodipine. Initiating treatment
with these FDC formulations was effective in controlling
about 50% of patients with stage 2, and 25% of patients with
stage 3 hypertension. Few patients discontinued treatment,
and the frequency of cough that interfered with sleep and
ankle edema was low.
Hypertension is a major risk factor of cardiovascular
mortality,1 and treatment to reduce blood pressure has been
shown to lower the frequency of coronary events.2 However,
this evidence is based on drug trials that recruited mostly
older patients. The impact of blood pressure lowering treat-
ment on both the extent of blood pressure decrease, and
reduction of cardiovascular risk in younger patients is un-
certain.3 In the absence of such evidence, the recent NICE
guidelines recommend that since younger patients tend to
have higher renin levels, an ACEI may be appropriate to
initiate treatment in patients below 55 years. If blood pressure
control is not achieved, the addition of a calcium channel
blocker (CCB), or alternatively a thiazide like diuretic such as
Indapamide, has been suggested. The guidelines also recom-
mend the use of long acting, once daily drug formulations to
enhance compliance with medication,3 and these study re-
sults appear to be in consonance with the NICE guidelines.
A search of the literature suggests that only a few studies
have assessed the effect of ACEI on the surrogate end point of
blood pressure reduction in younger patients.7e9 In compari-
son to full dose captopril,9 our result with the lowest dose of
perindopril (4 mg) or its FDC with 1.5 mg indapamide or 5 mg
amlodipine, decreased blood pressure to a greater degree (by
16/5 mm Hg), achieved a greater frequency of blood pressure
control (by 15%), with fewer withdrawals because of adverse
effects (by 3.5%).
Although the FDCs of perindopril with Indapamide and
amlodipine have not as yet been shown to reduce cardiovas-
cular risk in hypertension, recent studies have assessed the
two combinations with each agent given individually. In theASCOT study on high risk hypertensive patients, treatment
with amlodipine and perindopril for 5.5 years significantly
reduced all cause mortality, cardiovascular events, and
stroke.5 The HYVET study on elderly hypertensive patients,
showed that treatment with Indapamide and perindopril for 2
years significantly reduced risk of all cause and cardiovascular
mortality, stroke, and heart failure.6 The antihypertensive
efficacy and acceptability of an ACEI, alone, or in an FDC with
a CCB or Indapamide among younger patients has not previ-
ously been assessed, and the present study is the first to report
such results.
This study has limitations. The antihypertensive treat-
ments were not compared with other similar formulations
using a randomized protocol. The results are over the short
term, and the possible long term benefit was not assessed.
However, the strengths of this study are that it is on
younger patients, seen in day-to-day practice, and repre-
senting the heterogeneity of India. This may serve to clear the
doubt among Indian physicians that ACEIs have poor anti-
hypertensive efficacy with the reassurances that the inci-
dence of cough may be low with Perindopril.
The results of this study suggest that in younger patients
requiring guideline recommended antihypertensive treat-
ment, the regimen of perindopril alone or its FDC with Inda-
pamide or amlodipine reduces blood pressure effectively,
resulting in high rates of blood pressure control over the short
term, with a low frequency of side effects including cough and
pedal edema. Such treatment favors long term compliance
and could help increase the frequency of blood pressure
control among younger patients.Conflicts of interest
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